Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Humira adalimumab: Phase II; marketed for rheumatoid arthritis (RA) in

February 16, 2004 8:00 AM UTC

In a double-blind, North American Phase II trial in 148 patients, 53% of those receiving Humira 40 mg every other week and 80% of patients receiving Humira 40 mg weekly had a PASI 75 response, compare...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article